Catabasis Pharma (CATB) Stock Analyst Ratings
NASDAQ:CATB - Nasdaq -
ChartMill assigns a Buy % Consensus number of 100% to CATB. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 24.23. This target is 183.67% above the current price.
CATB was analyzed by 4 analysts. The buy percentage consensus is at 100. So analysts seem to be very confident about CATB.
In the last month the buy percentage rose by 13 points. So the trust of analysts is improving.
Only 4 analysts analyzed CATB. So this is just the average opinion of a couple of analysts.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2021-09-02 | Wedbush | Initiate | Outperform |
| 2021-08-25 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2021-05-12 | Ladenburg Thalmann | Initiate | Buy |
| 2021-03-11 | Oppenheimer | Upgrade | Perform -> Outperform |